Sunday, April 18, 2021

Sirnaomics Initiates Phase 2 Study Using STP705 for Keloid Scar Prevention

GAITHERSBURG, Md. and SUZHOU BIOBAY, China, April 18, 2021 /PRNewswire/ -- Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, today announced the initiation of a Phase 2 study of the company's...



from PR Newswire: https://ift.tt/3dsBvs5

No comments:

Post a Comment